<DOC>
	<DOCNO>NCT00487773</DOCNO>
	<brief_summary>The purpose trial check inhale glucocorticosteroids ( iGCS ) influence bone condition ( iGCS increase risk osteoporosis bone fraction ) child asthma .</brief_summary>
	<brief_title>Effect Different Doses Budesonide Markers Bone Metabolism Children With Asthma</brief_title>
	<detailed_description>Asthma prevalent chronic disease respiratory tract , large frequency notice child . iGCS basic group drug asthma , inflammatory character disease . All iGCS absorb systemic circulation ( small amount ) despite local exposition lung possess systemic effect . The purpose trial check iGCS influence bone condition ( iGCS increase risk osteoporosis bone fraction ) child asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Allergic house dust mites Never treat chronically ( long least 3 month ) antiasthmatic drug Newlydiagnosed nontreated asthma Must able inhale drug Other allergic disease require treatment glucocorticosteroids Other chronic disease Asthma exacerbation Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>asthma</keyword>
	<keyword>child</keyword>
	<keyword>inhaled glucocorticosteroids</keyword>
	<keyword>bone metabolism</keyword>
</DOC>